



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Anticancer agent 210

Cat. No.:	HY-162481
Molecular Formula:	C ₃₁ H ₃₁ BrFN ₇ O ₃
Molecular Weight:	648.53
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 210 (Compound 7a) is a Gefitinib (HY-50895) derivative. Anticancer agent 210 inhibits proliferation, migration and colony formation of cancer cells. Anticancer agent 210 induces apoptosis in cells H1299 ^[1] .																
In Vitro	<p>Anticancer agent 210 (0-32 μM, 48 h) inhibits proliferation of lung cancer cells NCI-H1299, A549, NCI-H1437, with IC₅₀s of 3.94, 3.16 and 1.84 μM, respectively^[1].</p> <p>Anticancer agent 210 (2-16 μM, 48 h) exhibits slightly cytotoxicity in normal hepatocytes L02, with IC₅₀ of 18.87 μM, and a survival rate >60%^[1].</p> <p>Anticancer agent 210 (4-16 μM, 48 h) induces apoptosis of non-small cell lung cancer cells through Bcl-2/caspase3/PARP pathway, inhibits NSCLC cell migration through suppression of MMP9 protein expression^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>NCI-H1299, A549, NCI-H1437</td> </tr> <tr> <td>Concentration:</td> <td>0-32 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell proliferation.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>NCI-H1299</td> </tr> <tr> <td>Concentration:</td> <td>4-16 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited expressions of Bcl-2, caspase9 and MMP9, upregulated levels of cleaved caspase 3 and PARP.</td> </tr> </table>	Cell Line:	NCI-H1299, A549, NCI-H1437	Concentration:	0-32 μ M	Incubation Time:	48 h	Result:	Inhibited cell proliferation.	Cell Line:	NCI-H1299	Concentration:	4-16 μ M	Incubation Time:	48 h	Result:	Inhibited expressions of Bcl-2, caspase9 and MMP9, upregulated levels of cleaved caspase 3 and PARP.
Cell Line:	NCI-H1299, A549, NCI-H1437																
Concentration:	0-32 μ M																
Incubation Time:	48 h																
Result:	Inhibited cell proliferation.																
Cell Line:	NCI-H1299																
Concentration:	4-16 μ M																
Incubation Time:	48 h																
Result:	Inhibited expressions of Bcl-2, caspase9 and MMP9, upregulated levels of cleaved caspase 3 and PARP.																
In Vivo	Anticancer agent 210 (400 mg/kg, p.o., single dose) exhibits no significant toxicity in Kunming mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																

REFERENCES

[1]. Gao E, et al., Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation. Sci Rep. 2024 Apr 22;14(1):9223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA